APOE ɛ4 carriership determines a faster plasma p-tau217 progression in Aβ-positive individuals.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Woo Marcel S, Macedo Arthur C, Hosseini Seyyed Ali, Therriault Joseph, Wang Yi-Ting, Rahmouni Nesrine, Aumont Étienne, Servaes Stijn, Tissot Cécile, Fernandez-Arias Jaime, Trudel Lydia, Hall Brandon, Bezgin Gleb, Quispialaya-Socualaya Kely, Goncalves Marina, Chan Tevy, Stevenson Jenna, Zheng Yansheng, Hopewell Robert, Mitchell Stuart, Lussier Firoza Z, Alzheimer's Disease Neuroimaging Initiative (ADNI), Vitali Paolo, Massarweh Gassan, Soucy Jean-Paul, Benedet Andréa L, Gauthier Serge, Zetterberg Henrik, Blennow Kaj, Pascoal Tharick A, Rosa-Neto Pedro
Аннотация
METHODS: We assessed longitudinal trajectories in plasma p-tau181, 217, and 231, in amyloid beta-positive (A+) and negative (A-) APOE ɛ4 carriers (E+) or non-carriers (E-). We included 2039 participants from the observational Translational Biomarkers in Aging and Dementia (TRIAD) and Alzheimer's Disease Neuroimaging Initiative cohorts, categorized into 840 A-E-, 251 A-E+, 386 A+E4-, and 616 A+E4+. Longitudinal data were available for 1045 participants.
RESULTS: In TRIAD, ALZpath p-tau217 (β = 0.45, p = 0.02) and p-tau217+Janssen (β = 0.67, p = 0.002), and in ADNI p-tau217 (β = 0.90, p = 0.002) increased faster in A+E4+. This was not the case in E- or A- individuals or for p-tau181 and p-tau231.
DISCUSSION: These findings suggest p-tau217 as a marker of faster progression in APOE ɛ4 carriers, highlighting its potential in disease stratification.
HIGHLIGHTS: Blood phosphorylated tau (p-tau)217 increases faster in apolipoprotein E (APOE) ɛ4 carriers with amyloid pathology. p-tau181 and p-tau231 do not increase faster in APOE ɛ4 carriers. APOE ɛ4 carriership does not change p-tau in individuals without amyloid pathology.